Nutra Pharma (NPHC) 10-Q 21 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 21, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-32141
Entity Registrant Name	NUTRA PHARMA CORP
Entity Central Index Key	0001119643
Entity Tax Identification Number	91-2021600
Entity Incorporation, State or Country Code	CA
Entity Address, Address Line One	1537 NW 65th Avenue
Entity Address, City or Town	Plantation
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33313
City Area Code	954
Local Phone Number	509–0911
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,596,852,214

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash		$ 90,910
Accounts receivable	21,580	45,998
Inventory, current portion	49,346	31,289
Other receivable	3,000	6,000
Convertible notes receivable	270,896	273,480
Prepaid expenses and other current assets	117,650	86,150
Total current assets	462,472	533,827
Inventory, less current portion	90,380	98,880
Property and equipment, net	85,606	44,701
Operating lease right-of-use assets	43,397	93,811
Security deposit	8,803	8,803
Total assets	690,658	780,022
Current liabilities:
Accounts payable	712,757	672,372
Accrued expenses	963,526	851,470
Accrued payroll due to officers	1,173,693	1,053,693
Deferred revenue to a related party	111,011
Accrued interest to related parties	145,508	147,768
Due to officer	61,439	199,726
Derivative liabilities	5,097,169	10,537,344
Other debt, net of discount, current portion	7,860,452	7,598,325
SBA notes payable, current portion	2,930	2,121
Operating lease obligations, current portion	20,003	77,673
Total current liabilities	16,148,488	21,140,492
Convertible note, less current portion	4,707	369,401
SBA notes payable, less current portion	146,970	147,779
Total liabilities	16,300,165	21,657,672
Commitments and Contingencies
Stockholders’ deficit:
Preferred stock, $0.001 par value, 20,000,000 shares authorized and 12,000,000 Series B Preferred shares issued and outstanding at September 30, 2022 and December 31, 2021	12,000	12,000
Common stock, $0.001 par value, 12,000,000,000 shares authorized: 7,596,852,214 and 7,330,985,964 shares issued and outstanding at September 30, 2022 and December 31, 2021	7,596,852	7,330,986
Additional paid-in capital	53,565,739	53,508,353
Accumulated deficit	(76,784,098)	(81,728,989)
Total stockholders’ deficit	(15,609,507)	(20,877,650)
Total liabilities and stockholders’ deficit	$ 690,658	$ 780,022

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	12,000,000,000	12,000,000,000
Common stock, shares issued	7,596,852,214	7,330,985,964
Common stock, shares outstanding	7,596,852,214	7,330,985,964
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	12,000,000	12,000,000
Preferred stock, shares outstanding	12,000,000	12,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net sales	$ 24,624	$ 19,266	$ 66,814	$ 71,748
Net sales to a related party	84,580		154,966
Cost of sales	(41,051)	(9,644)	(116,254)	(24,284)
Gross profit	68,153	9,622	105,526	47,464
Operating expenses:
Selling, general and administrative - including stock based compensation of $0 and $64,750 for the three months ended September 30, 2022 and 2021, and $20,500 and $66,195 for the nine months ended September 30, 2022 and 2021, respectively	326,473	556,932	991,557	1,501,689
Bad debt expense (recovery) - related party	(21,799)	(35,000)		38,000
Total operating expenses	304,674	521,932	991,557	1,539,689
Loss from operations	(236,521)	(512,310)	(886,031)	(1,492,225)
Other income (expenses)
Other income	4,210	4,750	16,215	6,465
Interest expense	(195,424)	(131,482)	(580,075)	(346,792)
Interest expense to related parties	(4,272)	(4,504)	(12,740)	(13,881)
Change in fair value of convertible notes and derivatives	1,019,736	16,133,270	6,569,581	(12,824,783)
Stock based loan modification cost	(10,500)		(10,500)	(107,500)
Loss on settlement of debt and accrued expense, net		(56,339)	(151,559)	(485,836)
Total other income (expenses)	813,750	15,945,695	5,830,922	(13,772,327)
Income (loss) before income taxes	577,229	15,433,385	4,944,891	(15,264,552)
Provision for income taxes
Net income (loss)	$ 577,229	$ 15,433,385	$ 4,944,891	$ (15,264,552)
Net income (loss) per share - basic and diluted	$ 0	$ 0	$ 0	$ 0
Weighted average number of shares outstanding during the period - basic	7,592,286,997	7,289,196,290	7,471,152,031	7,201,163,176
Weighted average number of shares outstanding during the period - diluted	15,597,613,916	12,670,053,386	15,104,777,470	7,201,163,176

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Stock based compensation	$ 0	$ 64,750	$ 20,500	$ 66,195

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 3,000		$ 6,955,197	$ 50,181,456	$ (68,633,468)	$ (11,493,815)
Beginning balance, shares at Dec. 31, 2020	3,000,000		6,955,197,214
Common stock issued for debt modification and penalty			$ 25,000	82,500		107,500
Common stock issued for debt modification and penalty, shares			25,000,000
Net income (loss)					(15,264,552)	(15,264,552)
Issuance of common stock in exchange for services to consultants			$ 25,000	125,000		150,000
Issuance of common stock in exchange for services to consultants, shares			25,000,000
Common stock issued for settlement of debt			$ 62,939	472,848		535,787
Common stock issued for settlement of debt, shares			62,938,750
Common stock issued for conversion of debt			$ 240,350	2,104,049		2,344,399
Common stock issued for conversion of debt, shares			240,350,000
Ending balance, value at Sep. 30, 2021	$ 3,000		$ 7,308,486	52,965,853	(83,898,020)	(23,620,681)
Ending balance, shares at Sep. 30, 2021	3,000,000		7,308,485,964
Beginning balance, value at Jun. 30, 2021	$ 3,000		$ 7,267,620	52,816,687	(99,331,405)	(39,244,098)
Beginning balance, shares at Jun. 30, 2021	3,000,000		7,267,619,714
Net income (loss)					15,433,385	15,433,385
Issuance of common stock in exchange for services to consultants			$ 20,000	97,000		117,000
Issuance of common stock in exchange for services to consultants, shares			20,000,000
Common stock issued for settlement of debt			$ 20,866	52,166		73,032
Common stock issued for settlement of debt, shares			20,866,250
Ending balance, value at Sep. 30, 2021	$ 3,000		$ 7,308,486	52,965,853	(83,898,020)	(23,620,681)
Ending balance, shares at Sep. 30, 2021	3,000,000		7,308,485,964
Beginning balance, value at Dec. 31, 2021		$ 12,000	$ 7,330,986	53,508,353	(81,728,989)	(20,877,650)
Beginning balance, shares at Dec. 31, 2021		12,000,000	7,330,985,964
Common stock issued for debt modification and penalty			$ 10,500			10,500
Common stock issued for debt modification and penalty, shares			10,500,000
Net income (loss)					4,944,891	4,944,891
Common stock issued for settlement of debt			$ 243,366	33,386		276,752
Common stock issued for settlement of debt, shares			243,366,250
Common stock issued for conversion of debt			$ 12,000	24,000		36,000
Common stock issued for conversion of debt, shares			12,000,000
Ending balance, value at Sep. 30, 2022		$ 12,000	$ 7,596,852	53,565,739	(76,784,098)	(15,609,507)
Ending balance, shares at Sep. 30, 2022		12,000,000	7,596,852,214
Beginning balance, value at Jun. 30, 2022		$ 12,000	$ 7,586,352	53,565,739	(77,361,327)	(16,197,236)
Beginning balance, shares at Jun. 30, 2022		12,000,000	7,586,352,214
Common stock issued for debt modification and penalty			$ 10,500			10,500
Common stock issued for debt modification and penalty, shares			10,500,000
Net income (loss)					577,229	577,229
Ending balance, value at Sep. 30, 2022		$ 12,000	$ 7,596,852	$ 53,565,739	$ (76,784,098)	$ (15,609,507)
Ending balance, shares at Sep. 30, 2022		12,000,000	7,596,852,214

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net income (loss)	$ 577,229		$ 15,433,385	$ 4,944,891	$ (15,264,552)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Bad debt expense - related party	(21,799)		(35,000)		38,000
Accrued interest expense for amount due to officer				3,512	5,788	$ 7,520
Loss on settlement of debt and accrued expense			56,339	151,559	485,836
Depreciation	5,898		2,793	17,088	6,178
Stock-based compensation	0		64,750	20,500	66,195
Stock-based loan modification cost	10,500			10,500	107,500
Amortization of convertible notes receivable discount				(16,215)	(6,465)
Change in fair value of convertible notes and derivatives	(1,019,736)		(16,133,270)	(6,569,581)	12,824,783
Amortization of loan discount				404,549	232,117
Amortization of operating lease right-of-use assets				50,414	35,995
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable				24,418	(4,359)
Increase in other receivable				(12,000)	(9,000)
Increase in inventory				(9,557)	(47,737)
Increase in prepaid expenses and other current assets				(52,000)	(98,150)
Decrease in accounts payable				40,385	12,516
Increase in accrued expenses				112,056	56,973
Increase in accrued payroll due to officers				120,000	125,500
Increase in deferred revenue to a related party				111,011
Decrease in accrued interest to related parties				(2,260)	(26,120)
Decrease in operating lease obligations				(57,670)	(51,787)
Net cash used in operating activities				(708,400)	(1,510,789)
Cash flows from investing activities:
Convertible notes receivable advances				(16,451)	(242,500)
Convertible notes receivable repayments	50,250			50,250
Acquisition of equipment				(57,993)	(34,768)
Net cash used in investing activities:				(24,194)	(277,268)
Cash flows from financing activities:
Loans from officer				62,201	56,900
Repayment of officer loans				(204,000)	(120,250)
Proceeds from convertible notes				710,000	1,976,560
Repayment of convertible notes				(60,994)	(65,028)
Advances from an unrelated third party				251,340
Repayments of other notes payable				(116,863)	(15,375)
Net cash provided by financing activities				641,684	1,832,807
Net increase(decrease) in cash				(90,910)	44,750
Cash - beginning of period		$ 44,750		90,910
Cash - end of period		$ 90,910	$ 44,750		44,750	$ 90,910
Supplemental Cash Flow Information:
Cash paid for interest				84,460	41,951
Cash paid for income taxes
Non Cash Financing and Investing:
Common stock issued in settlement of notes				287,252	535,787
Common stock issued for conversion of debt				36,000	2,344,399
Warrants issued with Debt--Debt discount				100,000
Increase of right-of-use asset due to lease renewal					4,102
Increase of operating lease liabilities due to lease renewal					4,102
Reclassification of rental receivable to convertible notes receivable				$ 15,000	$ 6,000

BASIS OF PRESENTATION AND SUMMA

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K from which the accompanying condensed consolidated balance sheet dated December 31, 2021 was derived. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $ 76,784,098 15,686,016 15,609,507 There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $ 64,895 150,000 The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. We classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at September 30, 2022 and December 31, 2021, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $ 0 48,000 294,162 Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended September 30, 2022, one customer accounted for 77 10 70 25 100 Operating Lease Right-of-Use Asset and Liability The Company accounts for leases in accordance with Accounting Standards Update (“ASU”) 2016-02, Leases In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to other income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that was issued before the adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity that did not contain an embedded derivative that required bifurcation, the conversion feature was evaluated to determine if the rate of conversion was below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt was recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt was recorded net of the discount for the BCF. The discount was amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, Derivatives and Hedging Embedded Derivatives Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 7 Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. Income Taxes The Company recorded no Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount (See Note 13). Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Income (Loss) Per Share Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share SCHEDULE OF NET INCOME (LOSS) PER SHARE 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Basic and diluted numerator: Net income (loss) - basic $ 577,229 $ 15,433,385 $ 4,944,891 $ (15,264,552 ) Effect of dilutive securities: Change in fair value of convertible notes (730,917 ) (2,595,948 ) (805,027 ) - Interest on convertible debt 61,313 91,454 213,995 - Net income (loss) - diluted $ (92,375 ) $ 12,928,891 $ 4,353,859 $ (15,264,552 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 7,592,286,997 7,289,196,290 7,471,152,031 7,201,163,176 Effect of dilutive securities: Convertible debt 8,005,326,919 5,380,857,096 7,633,625,439 - Options and warrants - - - - Weighted-average common shares outstanding - diluted (1) 15,597,613,916 12,670,053,386 15,104,777,470 7,201,163,176 Net income (loss) per share - basic and diluted $ (0.00 ) $ 0.00 $ 0.00 $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares. The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because for the three months ended September 30, 2022 and 2021, the exercise prices of the options and warrants were greater than the average market price of the common shares: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - - Convertible notes payable - - Total 447,014,285 108,175,000 The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because (1) for the nine months ended September 30, 2022, the exercise prices of the options and warrants were greater than the average market price of the common shares and (2) for the nine months ended September 30, 2021, the effect of including these potential shares was antidilutive due to a net loss: September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - 1,201,380,692 Convertible notes payable - 4,434,302,953 Total 447,014,285 5,743,858,645 Recent Adopted Accounting Pronouncements As of January 1, 2022, the Company adopted ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity As of January 1, 2022, the Company adopted ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. The adoption did not have a material effect on the accompanying consolidated financial statements. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at September 30, 2022 and December 31, 2021: SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 200,103 $        - $ - $ 200,103 Derivative liabilities $ 4,897,066 $ - $ 4,897,066 $ - Convertible notes at fair value $ 1,745,305 $ - $ - $ 1,745,305 Total Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 710,585 $        - $ - $ 710,585 Derivative liabilities $ 9,826,759 $ - $ 9,826,759 $ - Convertible notes at fair value $ 2,855,709 $ - $ - $ 2,855,709 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the nine months ended September 30, 2022 and the year ended December 31, 2021: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description September 30, 2022 December 31, 2021 Beginning balance $ 710,585 $ 189,543 Purchases, issuances, and settlements 100,000 590,885 Day one loss on value of hybrid instrument (1) Repayments in cash Conversion to common stock Total gain included in earnings (1) (1) (610,482 ) (69,843 ) Ending balance $ 200,103 $ 710,585 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 2.79 % to 3.92 % risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 411 %, (4) zero expected dividends, (5) exercise price set forth in the agreements, (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. We valued derivative liabilities using the number of potential convertible shares for warrants in equity and convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at September 30, 2022. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit and the equity environment is tainted, and therefore all convertible debt and options and warrants should be accounted for as liabilities. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at September 30, 2022 and December 31, 2021: SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS Conversion Price - Lower of Fixed Price or Percentage of VWAP for Look-back Period Debenture Face Amount Interest Rate Default Interest Rate Discount Rate Anti-Dilution Adjusted Price % of stock price for look-back period Look-back Period September 30, 2022 $ 711,446 8 10 20 24 N/A $ 0.00040 0.00048 50 60 3 25 December 31, 2021 $ 762,446 8 10 20 24 N/A $ 0.00050 0.00097 50 60 3 25 Using the stated assumptions summarized in the table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the nine months ended September 30, 2022 and the year ended December 31, 2021: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description September 30, 2022 December 31, 2021 Beginning balance $ 2,855,709 $ 1,832,439 Purchases and issuances - 132,000 Day one loss on value of hybrid instrument (1) (1) - 2,042,612 Loss (gain) from change in fair value (1) (1) (1,029,404 ) 1,233,538 Repayments in cash (45,000 ) (40,480 ) Conversion to common stock (36,000 ) (2,344,399 ) Ending balance $ 1,745,305 $ 2,855,709 (1) The losses (gains) related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
INVENTORIES	3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At September 30, 2022 and December 31, 2021, inventories were as follows: SCHEDULE OF INVENTORIES September 30, 2022 December 31, 2021 Raw Materials $ 131,005 $ 126,349 Finished Goods 8,721 3,820 Total Inventories 139,726 130,169 Less: Long-term inventory (90,380 ) (98,880 ) Current portion $ 49,346 $ 31,289

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at September 30, 2022 and December 31, 2021: SCHEDULE OF PROPERTY AND EQUIPMENT September 30, 2022 December 31, 2021 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 162,557 104,564 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 324,879 266,886 Less: Accumulated depreciation (239,273 ) (222,185 ) Property and equipment, net $ 85,606 $ 44,701 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At September 30, 2022, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the nine-months ended September 30, 2022 and 2021 was $ 17,088 6,178 5,898 2,793

DUE TO_FROM OFFICER

DUE TO/FROM OFFICER	9 Months Ended
	Sep. 30, 2022
Due Tofrom Officer
DUE TO/FROM OFFICER	5. DUE TO/FROM OFFICER At September 30, 2022, the net balance due to Rik Deitsch, and the companies majority owned and controlled by him (collectively referred to as “Due to Officer”) in the aggregate is $ 61,439 , which net balance is unsecured and accruing interest at 4 204,000 and were advanced $ 62,201 on this balance. Additionally, accrued interest on the outstanding balance was $ 3,512 and is included in the due to officer account. The Company had previously fully reserved receivables from companies owned by the Company’s CEO. For the nine months ended September 30, 2021, we recorded a bad debt expense of $ 38,000 21,799 and $ 35,000 , respectively. At December 31, 2021, the net balance due to Rik Deitsch, and the companies majority owned and controlled by him is $ 199,726 4 182,741 105,780 7,520

DEBTS

DEBTS	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
DEBTS	6. DEBTS Debts consist of the following at September 30, 2022 and December 31, 2021: SCHEDULE OF DEBT September 30, 2022 December 31, 2021 Notes payable – Unrelated third parties (Net of discount of $ 19,106 0 $ 1,285,287 $ 1,135,257 Convertible notes payable – Unrelated third parties (Net of discount of $ 183,570 283,429 4,609,567 3,751,760 Convertible notes payable, at fair value (4) 1,745,305 2,855,709 Other advances from an unrelated third party (5) 225,000 225,000 SBA notes payable(6) 149,900 149,900 Ending balances 8,015,059 8,117,626 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (4,707 ) (369,401 ) Less: Long-term portion- SBA notes payable (146,970 ) (146,970 ) Current portion $ 7,863,382 $ 7,600,446 (1) During 2010 we borrowed $ 200,000 nine months interest calculated at 10% for the first month plus 12% December 31, 2016 40,000 10,000 15,000 145,508 147,768 4,272 4,504 12,740 13,881 (2) At September 30, 2022 and December 31, 2021, the balance of $ 1,285,287 1,135,257 19,106 0 ● In August 2016, we issued two Promissory Notes for a total of $ 200,000 100,000 12% 101,818 21,023 104,000 88,500 15,500 88,500 91,156 60,037 51,856 The remaining principal balance of $91,156 and accrued interest of $60,037 is being disputed in court and negotiation for settlement ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $ 350,000 50,000 175,000 25,000 25,000 142,858 5,714,326 450,000 350,000 100,000 281,772 281,772 ● At December 31, 2012, we owed University Centre West Ltd. approximately $ 55,410 ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $ 10,000 10% 6,541 5,783 ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $ 75,000 2% 5,000,000 25,000 50,000 83,434 74,334 ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $ 50,000 2% 50,000 76,634 67,534 ● A promissory note originally issued to an unrelated third party in August 2016 was restated in September 2019 in the amount of $ 333,543 2.0% 20,000,000 10,000,000 6,000 5,895 333,543 248,378 187,673 ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $ 75,000 10% 15,000 60,000 15,900 15,000 1,371 ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $ 50,000 2% 72,934 63,834 ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $ 12,500 10% 6,698 5,750 ● During July 2017, we received a loan for a total of $ 200,000 15% 130,401 40,000 5,000 2,000 34,976 42,698 44,478 14,376 33,874 130,401 33,874 ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $ 50,000 10,000 50,000 ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $ 120,000 20,000 50,000 125,000,000 87,500 37,500 36,000,000 10,000,000 32,200 70,000 14,000 10,000 74,000 74,000 ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $ 18,000 3,000 18,000 2,000 ● During January 2022, the Company received a loan for $ 199,000 63.76% 4,975 850 2,300 68,023 2,675 130,977 ● During June 2022, the Company entered a Purchase and Sale of Future Receipts Agreement with a non-related party. This third party purchased $ 87,000 60,000 87,000 29,685 12,369 885 38,839 16,431 31,730 (3) At September 30, 2022 and December 31, 2021, the balance of $ 4,609,567 3,751,760 183,570 283,429 ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $ 60,000 10,000 60,000 ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $ 618,250 62,950 0.0003 0.001 255,655 62,950 28,421 During February 2019, we issued convertible notes payable of $ 55,000 5,000 0.0005 55,000 9,200 128,400 0.001 92,100,000 36,300,000 541 195,178 During May 2019, we restated two convertible notes payable with additional original issue discount of $ 6,400 During February, November and December 2019, we issued three convertible promissory notes to the unrelated third party for $ 174,500 14,500 0.0002 0.000275 During 2019, repayments of $ 13,500 87,100 800,000,000 At December 31, 2019, the principal balance of the notes, net of discount of $ 17,370 736,180 17,370 10,000 During the year ended December 31, 2020, we issued convertible notes payable of $ 555,600 53,600 287,400 268,200 0.0002 0.0008 1,000,000 22,000 700 57,500 7,500 71,875,000 0.002 50,000 7,500 0 106,032 At December 31, 2020, the principal balance of the notes, net of discount of $ 101,448 1,276,902 83,720 During the first quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $ 717,667 93,609 864,225 112,725 539,351 70,350 358,800 46,800 0.0003 0.002 228,563 August 29, 2022 During December 2021, in connection with the issuance of three of the above mentioned convertible notes of $ 172,500 22,500 246,428,571 0.002 150,000 22,500 105,814 409,374 During March 2021, the remaining balance of promissory note of $ 30,000 0.01 12% 1,000 7,323 7,244 15,433 22,677 513 793 1,756 1,951 During March 2021, in connection with the settlement of the $ 6,000 11,000 11,000,000 6,000 104,500 5,000 98,500 8,500 12,000 2,000,000 4,000 15,200 4,500 11,200 During August 2021, the promissory note of $ 166,926 0.002 183,619 16,693 20,866,250 16,693 54,252 16,693 37,559 166,926 0.002 16,693 10,000,000 10,000 10,000 166,926 16,693 0.002 16,693 During the first quarter of 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 172,500 22,500 0.0005 0.0008 During the second quarter of 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 379,500 49,500 0.0006 0.0008 During the third quarter of 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 264,500 34,500 0.0005 0.0006 During January and May 2022, in connection with the issuance of one of the above mentioned convertible notes of $ 115,000 15,000 164,285,714 0.002 100,000 15,000 93,748 During June 2022, we repaid a convertible notes payable originated in May 2021 in cash for $ 5,750 108,500 222,500,000 108,500 222,500 114,000 During August 2022, we made repayment of $ 3,000 17,250 3,000 500,000 500 500 At the date of this report, $ 3,125,268 The total discount amortization on all notes for the three and nine months ended September 30, 2021 was $ 123,813 388,994 91,455 213,924 183,570 4,609,567 283,430 3,751,760 (4) At September 30, 2022 and December 31, 2021, the balance of $ 1,745,305 2,855,709 ● The remaining balance of $ 20,000 120,000 55% 20,000 24,217 21,183 80,395 84,768 ● During May 2017, we issued a Convertible Debenture in the amount of $ 64,000 May 4, 2018 60% twenty 20% 12,629 16,728 14,834 48,929 70,418 ● During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. During October 2020, the Note holder sold the remaining debt principal value as of October 22, 2020 of $ 509,301 234,417 250,000 250,000 8% 286,969 We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date 275,000 82,022 32,657 714,044 946,639 ● During July 2018, we issued a convertible debenture in the amount of $ 50,000 8% 24% 46,734 50,000 42,367 33,490 167,940 202,491 ● During August 2018, we issued a convertible debenture in the amount of $ 20,000 8% 24% 17,829 20,000 16,500 12,923 66,363 79,815 ● During January 2019, the principal balance of $ 60,000 75,000 15,900 75,900 50% 75,900 20,000 75,900 100,000,000 20,000 140,000 55,900 111,800 156,000 ● During February 2019, we issued a convertible promissory note to an unrelated third party in the amount up to $ 1,000,000 0.0005 372,374 20,199 132,000 40,480 45,000 27,000 11,412 2,042,612 750,000,000 100,000 275,000 500,000,000 175,000 425,000 240,350,000 120,175 2,344,399 12,000,000 6,000 36,000 37,917 37,917 88,917 75,834 355,668 ● During June 2019, we issued a convertible promissory note to an unrelated third party for $ 240,000 40,000 16,000,000 4,688 The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion 240,000 240,000 480,000 960,000 (5) At September 30, 2022 and December 31, 2021, the balance of $ 225,000 (6) During May 2020, we entered into a two-year loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $ 64,895 1% During April and June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) considering the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $ 150,000 3.75% 731 5,000 13,124 8,906 SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT Years Amount 2022(2 months remaining) $ 525 2023 3,222 2024 3,345 2025 3,472 2026 3,605 Thereafter 135,731 149,900 Less: Long-term portion - SBA notes payable (146,970 ) Current portion $ 2,930

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	7. STOCKHOLDERS’ DEFICIT Authorized Shares On November 18, 2021, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 8,000,000,000 12,000,000,000 Series A Preferred Stock Effective October 30, 2017, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination to authorize the issuance of 20,000,000 Effective October 30, 2017 the Board of Directors authorized the issuance of 3,000,000 1. The Series A Preferred voted with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series A Preferred is entitled to one thousand votes per share. 2. The Series A Preferred was not entitled to dividends unless the Company paid cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series A Preferred was entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series A Preferred would have the same record and payment date and terms as the dividend payable on the common stock. 3. The Series A Preferred did not have any redemption rights. Effective November 15, 2021, the Board of Directors authorized an exchange of 3,000,000 Upon return of 100% of Series A Preferred Stock to the Company, the entire class of Series A Preferred Stock was cancelled and the associated Certificate of Determination was filed with the Secretary of State of California. Series B Preferred Stock Effective March 2021, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination for its Series B Preferred Stock. The Series B Preferred Stock has a par value of $ 0.001 12,000,000 Terms of the Series B Preferred include the following: 1. The Series B Preferred votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series B Preferred is entitled to one thousand votes per share. 2. The Series B Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series B Preferred will be entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series B Preferred will have the same record and payment date and terms as the dividend payable on the common stock. The liquidation value of Series B Preferred is $ 0 3. Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series B Preferred then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount in cash equal to $ 0.133 4. The Series B Preferred does not have any redemption rights. During November 2021, the Board of Directors approved resolutions for the issuance of a total of 9,000,000 540,000 Effective November 15, 2021, the Board of Directors authorized an exchange of 3,000,000 Common Stock Issued for Conversion of Convertible Debt During February 2022, the Noteholder received 12,000,000 6,000 36,000 Common Stock Issued for Settlement of Debt During February 2022, in connection with the settlement of $ 16,693 183,619 20,866,250 54,252 37,559 During May 2022, in connection with the settlement of a total of $ 108,500 222,500,000 108,500 222,500 114,000 Common Stock Issued for Debt Modification and Penalty During August 2022, we issued 10,000,000 183,619 10,000 During August 2022, we issued 500,000 17,250 500 Common Stock Issued for Consulting Service During July 2021, the Company signed an agreement with a consultant for services for twelve months. The 5,000,000 41,000 0 20,500

STOCK WARRANTS

STOCK WARRANTS	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK WARRANTS	8. STOCK WARRANTS Common Stock Warrants During August 2020, convertible promissory notes of $ 38,500 7,550 16,500 1,650 0.001 541 195,178 SCHEDULE OF WARRANTS ISSUED Month of Issuance Number of Warrants Month of Expiration August, 2020 92,100,000 August, 2022 October, 2020 36,300,000 October, 2022 During November and December, 2020, the Company granted the 71,875,000 0.002 57,500 7,500 57,500 0 106,032 During December 2021, in connection with the issuance of three of the convertible notes of $ 172,500 22,500 246,428,571 0.002 105,814 409,374 During January and May 2022, in connection with the issuance of the convertible note of $ 115,000 15,000 164,285,714 0.002 93,748 A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2021 and the nine months ended September 30, 2022: SUMMARY OF WARRANTS OUTSTANDING Number Of Weighted Balance December 31, 2020 202,775,000 $ 0.0017 Exercised - - Issued 410,403,571 0.0014 Expired (166,475,000 ) 0.0015 Balance December 31, 2021 446,703,571 $ 0.0017 Exercised - - Issued 164,285,714 0.0020 Expired (163,975,000 ) 0.0014 Balance September 30, 2022 447,014,285 $ 0.0019 The following table summarizes information about fixed-price warrants outstanding as of September 30, 2022 and December 31, 2021 : SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price September 30, 2022 $ 0.001 0.002 447,014,285 0.30 $ 0.0019 December 31, 2021 $ 0.001 0.002 446,703,571 0.67 $ 0.0017 At September 30, 2022, the aggregate intrinsic value of all warrants outstanding and expected to vest was $ 0 0.0008 no

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES	9. ACCRUED EXPENSES Accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES September 30, 2022 December 31, Accrued consulting fees $ 161,550 $ 161,550 Accrued payroll taxes 227,912 215,543 Accrued interest 571,151 469,040 Accrued others 2,913 5,337 Total $ 963,526 $ 851,470

PREPAID EXPENSES

PREPAID EXPENSES	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses
PREPAID EXPENSES	10. PREPAID EXPENSES Prepaid expenses and other current assets consist of the following: SCHEDULE OF PREPAID EXPENSES September 30, 2022 December 31, Supplier advances for future purchases $ 339,162 $ 294,162 Reserve for supplier advances (294,162 ) (294,162 ) Net supplier advances 45,000 - Prepaid professional fees 72,650 65,650 Deferred stock compensation - 20,500 Total $ 117,650 $ 86,150 We performed an evaluation of our inventory and related accounts at September 30, 2022 and December 31, 2021, and increased the reserve on supplier advances for future venom purchases by $ 0 48,000 294,162

CONVERTIBLE NOTES RECEIVABLE

CONVERTIBLE NOTES RECEIVABLE	9 Months Ended
	Sep. 30, 2022
Convertible Notes Receivable
CONVERTIBLE NOTES RECEIVABLE	11. CONVERTIBLE NOTES RECEIVABLE During March through November 2021, we purchased five convertible notes from an unrelated third party (the “Third Party”) for a total of $ 286,550 26,050 0.01 one year During March through September 2022, we purchased five convertible notes from the Third Party for a total of $ 34,596 3,145 0.01 Repayments of $ 50,250 0 13,070 270,896 273,480 Amortization for all the convertible notes receivable was $ 4,210 4,750 16,215 6,465 268,750

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	12. COMMITMENTS AND CONTINGENCIES Operating Leases ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $ 6,900 In February of 2021, we signed an updated lease with extended terms through January 1, 2023. The lease calls for monthly payments of approximately $ 6,500 SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION September 30, December 31, 2022 2021 Lease cost Operating lease cost $ 60,297 $ 80,396 Short-term lease cost - - Total lease cost $ 60,297 $ 80,396 Balance sheet information Operating ROU Assets $ 43,397 $ 93,811 Operating lease obligations, current portion 20,003 77,673 Operating lease obligations, non-current portion - - Total operating lease obligations $ 20,003 $ 77,673 Weighted average remaining lease term (in years) – operating leases 0.25 1 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows: Cash paid for amounts included in the measurement of operating lease liabilities $ 67,553 $ 95,846 Future minimum payments under these lease agreements are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 (Remaining three months) $ 20,270 Total future lease payments $ 20,270 Less imputed interest 267 Total $ 20,003 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years 500,000 8 50,000 0.18 142,500 During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 3,000 31,750 1,000,000 19,150 1,500,000 Litigation CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $ 100,000 91,156 60,037 Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants’ filed a Memorandum of Law in Opposition to Plaintiff’s Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021. On August 31, 2022, the Court entered an Order Granting in Part and Denying in Part the SEC’s Motion for Partial Summary Judgment. Specifically, the Court granted the SEC’s Motion for Partial Summary Judgment on Claim 7 (Section 5 of the Securities Act) against the Company and Mr. Deitsch, Claim 8 (Section 13(d) of the Exchange Act and Rule 13d-2(a) thereunder) against Mr. Deitsch, Claim 9 (Section 16(a) of the Exchange Act and Rule 16a-3 thereunder) against Mr. Deitsch, and Claim 10 (Section 13(a) of the Exchange Act and Rule 13a-11 thereunder) against the Company, but denied the SEC’s Motion for Partial Summary Judgment on Claim 14 (alleged aiding and abetting Nutra Pharma’s violation of Section 13(a) of the Exchange Act, and Rule 13a-11 thereunder) against Mr. Deitsch. The remedies pertaining to the claims addressed in the SEC’s Partial Summary Judgment will be determined by the Court at a later date. On September 16, 2022, Mr. Deitsch filed a Motion to Supplement his Initial Disclosures pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure and to re-open discovery for the limited purpose of obtaining discovery from certain Nutra Pharma shareholders identified by Mr. Deitsch in his supplement to the initial disclosures. The Magistrate Judge assigned to the case granted Deitsch’s Motion on that same day and discovery has been re-opened on a limited basis. When the discovery in the case is complete, the case will proceed to trial on the remaining claims in the SEC’s Second Amended Complaint that were not addressed in the SEC’s Partial Summary Judgment. The Company disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	13. RELATED PARTY TRANSACTIONS The Company acts as a product formulator and contract manufacturer for Avini Health. The Company’s chief executive officer is an owner of Avini Health and is its chief scientific officer. Commencing in May 2022, the Company sublets a portion of its space to Avini Health under a one-year sublease for a monthly rent of $ 5,000 10,000 As of September 30, 2022 and December 31, 2021, we had the following related party balances: SCHEDULE OF RELATED PARTY BALANCES September 30, December 31, 2022 2021 Deferred revenue to a related party $ 111,011 $ - Accrued interest to a related party 145,508 147,768 For the three and nine months ended September 30, 2022 and 2021, we had the following related party transactions SCHEDULE OF RELATED PARTY TRANSACTIONS 2022 2021 2022 2021 For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Net sales to a related party $ 84,580 $ - $ 154,966 $ - Bad debt expense (recovery) - related party (21,799 ) (35,000 ) - 38,000 Rental income from a related party 10,000 - 10,000 - Interest expense to a related party 4,272 4,504 12,740 13,881

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	14. SUBSEQUENT EVENTS During October 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 57,500 7,500 0.0006 On October 27, 2022, the promissory note of $ 199,000 199,000 60.73

BASIS OF PRESENTATION AND SUM_2

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Organization	Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ®
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K from which the accompanying condensed consolidated balance sheet dated December 31, 2021 was derived. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation.
Liquidity and Going Concern	Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $ 76,784,098 15,686,016 15,609,507 There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Impact of COVID-19 on our Operations	Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $ 64,895 150,000 The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine.
Use of Estimates	Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
Revenue from Contracts with Customers	Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts.
Accounting for Shipping and Handling Costs	Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No
Inventories	Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. We classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at September 30, 2022 and December 31, 2021, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $ 0 48,000 294,162
Financial Instruments and Concentration of Credit Risk	Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended September 30, 2022, one customer accounted for 77 10 70 25 100
Operating Lease Right-of-Use Asset and Liability	Operating Lease Right-of-Use Asset and Liability The Company accounts for leases in accordance with Accounting Standards Update (“ASU”) 2016-02, Leases In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate.
Derivative Financial Instruments	Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to other income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Convertible Debt	Convertible Debt For convertible debt that was issued before the adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity that did not contain an embedded derivative that required bifurcation, the conversion feature was evaluated to determine if the rate of conversion was below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt was recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt was recorded net of the discount for the BCF. The discount was amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note.
The Fair Value Measurement Option	The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging
Derivative Accounting for Convertible Debt and Options and Warrants	Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, Derivatives and Hedging Embedded Derivatives
Property and Equipment	Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 7
Long-Lived Assets	Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets.
Income Taxes	Income Taxes The Company recorded no
Related Party Transactions	Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount (See Note 13).
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation
Net Income (Loss) Per Share	Net Income (Loss) Per Share Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share SCHEDULE OF NET INCOME (LOSS) PER SHARE 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Basic and diluted numerator: Net income (loss) - basic $ 577,229 $ 15,433,385 $ 4,944,891 $ (15,264,552 ) Effect of dilutive securities: Change in fair value of convertible notes (730,917 ) (2,595,948 ) (805,027 ) - Interest on convertible debt 61,313 91,454 213,995 - Net income (loss) - diluted $ (92,375 ) $ 12,928,891 $ 4,353,859 $ (15,264,552 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 7,592,286,997 7,289,196,290 7,471,152,031 7,201,163,176 Effect of dilutive securities: Convertible debt 8,005,326,919 5,380,857,096 7,633,625,439 - Options and warrants - - - - Weighted-average common shares outstanding - diluted (1) 15,597,613,916 12,670,053,386 15,104,777,470 7,201,163,176 Net income (loss) per share - basic and diluted $ (0.00 ) $ 0.00 $ 0.00 $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares. The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because for the three months ended September 30, 2022 and 2021, the exercise prices of the options and warrants were greater than the average market price of the common shares: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - - Convertible notes payable - - Total 447,014,285 108,175,000 The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because (1) for the nine months ended September 30, 2022, the exercise prices of the options and warrants were greater than the average market price of the common shares and (2) for the nine months ended September 30, 2021, the effect of including these potential shares was antidilutive due to a net loss: September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - 1,201,380,692 Convertible notes payable - 4,434,302,953 Total 447,014,285 5,743,858,645
Recent Adopted Accounting Pronouncements	Recent Adopted Accounting Pronouncements As of January 1, 2022, the Company adopted ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity As of January 1, 2022, the Company adopted ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. The adoption did not have a material effect on the accompanying consolidated financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

BASIS OF PRESENTATION AND SUM_3

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SCHEDULE OF NET INCOME (LOSS) PER SHARE	SCHEDULE OF NET INCOME (LOSS) PER SHARE 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Basic and diluted numerator: Net income (loss) - basic $ 577,229 $ 15,433,385 $ 4,944,891 $ (15,264,552 ) Effect of dilutive securities: Change in fair value of convertible notes (730,917 ) (2,595,948 ) (805,027 ) - Interest on convertible debt 61,313 91,454 213,995 - Net income (loss) - diluted $ (92,375 ) $ 12,928,891 $ 4,353,859 $ (15,264,552 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 7,592,286,997 7,289,196,290 7,471,152,031 7,201,163,176 Effect of dilutive securities: Convertible debt 8,005,326,919 5,380,857,096 7,633,625,439 - Options and warrants - - - - Weighted-average common shares outstanding - diluted (1) 15,597,613,916 12,670,053,386 15,104,777,470 7,201,163,176 Net income (loss) per share - basic and diluted $ (0.00 ) $ 0.00 $ 0.00 $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares.
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE	The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because for the three months ended September 30, 2022 and 2021, the exercise prices of the options and warrants were greater than the average market price of the common shares: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - - Convertible notes payable - - Total 447,014,285 108,175,000 The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because (1) for the nine months ended September 30, 2022, the exercise prices of the options and warrants were greater than the average market price of the common shares and (2) for the nine months ended September 30, 2021, the effect of including these potential shares was antidilutive due to a net loss: September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - 1,201,380,692 Convertible notes payable - 4,434,302,953 Total 447,014,285 5,743,858,645

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2022
Short-Term Debt [Line Items]
SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE	The following table summarizes our financial instruments measured at fair value at September 30, 2022 and December 31, 2021: SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 200,103 $        - $ - $ 200,103 Derivative liabilities $ 4,897,066 $ - $ 4,897,066 $ - Convertible notes at fair value $ 1,745,305 $ - $ - $ 1,745,305 Total Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 710,585 $        - $ - $ 710,585 Derivative liabilities $ 9,826,759 $ - $ 9,826,759 $ - Convertible notes at fair value $ 2,855,709 $ - $ - $ 2,855,709
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS	The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the nine months ended September 30, 2022 and the year ended December 31, 2021: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description September 30, 2022 December 31, 2021 Beginning balance $ 710,585 $ 189,543 Purchases, issuances, and settlements 100,000 590,885 Day one loss on value of hybrid instrument (1) Repayments in cash Conversion to common stock Total gain included in earnings (1) (1) (610,482 ) (69,843 ) Ending balance $ 200,103 $ 710,585 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.
SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS	The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at September 30, 2022 and December 31, 2021: SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS Conversion Price - Lower of Fixed Price or Percentage of VWAP for Look-back Period Debenture Face Amount Interest Rate Default Interest Rate Discount Rate Anti-Dilution Adjusted Price % of stock price for look-back period Look-back Period September 30, 2022 $ 711,446 8 10 20 24 N/A $ 0.00040 0.00048 50 60 3 25 December 31, 2021 $ 762,446 8 10 20 24 N/A $ 0.00050 0.00097 50 60 3 25
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS	SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description September 30, 2022 December 31, 2021 Beginning balance $ 2,855,709 $ 1,832,439 Purchases and issuances - 132,000 Day one loss on value of hybrid instrument (1) (1) - 2,042,612 Loss (gain) from change in fair value (1) (1) (1,029,404 ) 1,233,538 Repayments in cash (45,000 ) (40,480 ) Conversion to common stock (36,000 ) (2,344,399 ) Ending balance $ 1,745,305 $ 2,855,709 (1) The losses (gains) related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories are valued at the lower of cost or net realizable value on an average cost basis. At September 30, 2022 and December 31, 2021, inventories were as follows: SCHEDULE OF INVENTORIES September 30, 2022 December 31, 2021 Raw Materials $ 131,005 $ 126,349 Finished Goods 8,721 3,820 Total Inventories 139,726 130,169 Less: Long-term inventory (90,380 ) (98,880 ) Current portion $ 49,346 $ 31,289

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Property and equipment consists of the following at September 30, 2022 and December 31, 2021: SCHEDULE OF PROPERTY AND EQUIPMENT September 30, 2022 December 31, 2021 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 162,557 104,564 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 324,879 266,886 Less: Accumulated depreciation (239,273 ) (222,185 ) Property and equipment, net $ 85,606 $ 44,701

DEBTS (Tables)

DEBTS (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
SCHEDULE OF DEBT	Debts consist of the following at September 30, 2022 and December 31, 2021: SCHEDULE OF DEBT September 30, 2022 December 31, 2021 Notes payable – Unrelated third parties (Net of discount of $ 19,106 0 $ 1,285,287 $ 1,135,257 Convertible notes payable – Unrelated third parties (Net of discount of $ 183,570 283,429 4,609,567 3,751,760 Convertible notes payable, at fair value (4) 1,745,305 2,855,709 Other advances from an unrelated third party (5) 225,000 225,000 SBA notes payable(6) 149,900 149,900 Ending balances 8,015,059 8,117,626 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (4,707 ) (369,401 ) Less: Long-term portion- SBA notes payable (146,970 ) (146,970 ) Current portion $ 7,863,382 $ 7,600,446
SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT	SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT Years Amount 2022(2 months remaining) $ 525 2023 3,222 2024 3,345 2025 3,472 2026 3,605 Thereafter 135,731 149,900 Less: Long-term portion - SBA notes payable (146,970 ) Current portion $ 2,930

STOCK WARRANTS (Tables)

STOCK WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF WARRANTS ISSUED	SCHEDULE OF WARRANTS ISSUED Month of Issuance Number of Warrants Month of Expiration August, 2020 92,100,000 August, 2022 October, 2020 36,300,000 October, 2022
SUMMARY OF WARRANTS OUTSTANDING	A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2021 and the nine months ended September 30, 2022: SUMMARY OF WARRANTS OUTSTANDING Number Of Weighted Balance December 31, 2020 202,775,000 $ 0.0017 Exercised - - Issued 410,403,571 0.0014 Expired (166,475,000 ) 0.0015 Balance December 31, 2021 446,703,571 $ 0.0017 Exercised - - Issued 164,285,714 0.0020 Expired (163,975,000 ) 0.0014 Balance September 30, 2022 447,014,285 $ 0.0019
SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING	The following table summarizes information about fixed-price warrants outstanding as of September 30, 2022 and December 31, 2021 : SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price September 30, 2022 $ 0.001 0.002 447,014,285 0.30 $ 0.0019 December 31, 2021 $ 0.001 0.002 446,703,571 0.67 $ 0.0017

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES	Accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES September 30, 2022 December 31, Accrued consulting fees $ 161,550 $ 161,550 Accrued payroll taxes 227,912 215,543 Accrued interest 571,151 469,040 Accrued others 2,913 5,337 Total $ 963,526 $ 851,470

PREPAID EXPENSES (Tables)

PREPAID EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses
SCHEDULE OF PREPAID EXPENSES	Prepaid expenses and other current assets consist of the following: SCHEDULE OF PREPAID EXPENSES September 30, 2022 December 31, Supplier advances for future purchases $ 339,162 $ 294,162 Reserve for supplier advances (294,162 ) (294,162 ) Net supplier advances 45,000 - Prepaid professional fees 72,650 65,650 Deferred stock compensation - 20,500 Total $ 117,650 $ 86,150

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION	SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION September 30, December 31, 2022 2021 Lease cost Operating lease cost $ 60,297 $ 80,396 Short-term lease cost - - Total lease cost $ 60,297 $ 80,396 Balance sheet information Operating ROU Assets $ 43,397 $ 93,811 Operating lease obligations, current portion 20,003 77,673 Operating lease obligations, non-current portion - - Total operating lease obligations $ 20,003 $ 77,673 Weighted average remaining lease term (in years) – operating leases 0.25 1 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows: Cash paid for amounts included in the measurement of operating lease liabilities $ 67,553 $ 95,846
SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE	Future minimum payments under these lease agreements are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 (Remaining three months) $ 20,270 Total future lease payments $ 20,270 Less imputed interest 267 Total $ 20,003

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
SCHEDULE OF RELATED PARTY BALANCES	As of September 30, 2022 and December 31, 2021, we had the following related party balances: SCHEDULE OF RELATED PARTY BALANCES September 30, December 31, 2022 2021 Deferred revenue to a related party $ 111,011 $ - Accrued interest to a related party 145,508 147,768
SCHEDULE OF RELATED PARTY TRANSACTIONS	For the three and nine months ended September 30, 2022 and 2021, we had the following related party transactions SCHEDULE OF RELATED PARTY TRANSACTIONS 2022 2021 2022 2021 For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Net sales to a related party $ 84,580 $ - $ 154,966 $ - Bad debt expense (recovery) - related party (21,799 ) (35,000 ) - 38,000 Rental income from a related party 10,000 - 10,000 - Interest expense to a related party 4,272 4,504 12,740 13,881

SCHEDULE OF NET INCOME (LOSS) P

SCHEDULE OF NET INCOME (LOSS) PER SHARE (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Net income (loss) - basic		$ 577,229	$ 15,433,385	$ 4,944,891	$ (15,264,552)
Change in fair value of convertible notes		(730,917)	(2,595,948)	(805,027)
Interest on convertible debt		61,313	91,454	213,995
Net income (loss) - diluted		$ (92,375)	$ 12,928,891	$ 4,353,859	$ (15,264,552)
Weighted-average common shares outstanding - basic		7,592,286,997	7,289,196,290	7,471,152,031	7,201,163,176
Convertible debt		8,005,326,919	5,380,857,096	7,633,625,439
Options and warrants
Weighted-average common shares outstanding - diluted	[1]	15,597,613,916	12,670,053,386	15,104,777,470	7,201,163,176
Net income (loss) per share - basic and diluted		$ 0	$ 0	$ 0	$ 0
[1]Includes potential common shares that are in excess of authorized shares.

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	447,014,285	108,175,000	447,014,285	5,743,858,645
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	447,014,285	108,175,000	447,014,285	108,175,000
Convertible Notes Payable Fair Value [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total				1,201,380,692
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total				4,434,302,953

BASIS OF PRESENTATION AND SUM_4

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	May 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020
Product Information [Line Items]
Accumulated deficit		$ 76,784,098			$ 76,784,098		$ 81,728,989
Working capital		15,686,016			15,686,016
stockholders' deficit		15,609,507	$ 23,620,681		15,609,507	$ 23,620,681	20,877,650	$ 16,197,236	$ 39,244,098	$ 11,493,815
Allowance for doubtful account		0			0		0
Change in reserve for supplier advances for purchases					0		48,000
Inventory valuation allowance		294,162			294,162		$ 294,162
Income tax expense
Minimum [Member]
Product Information [Line Items]
Property and equipment estimated useful lives					3 years
Maximum [Member]
Product Information [Line Items]
Property and equipment estimated useful lives					7 years
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk, percentage		77%	10%		70%	25%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk, percentage					100%		100%
Economic Injury Disaster Loan Assistance Program [Member]
Product Information [Line Items]
Loan amount				$ 150,000
SBA Loan Agreement [Member]
Product Information [Line Items]
Proceeds form loan	$ 64,895

SUMMARY OF FINANCIAL INSTRUMENT

SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 200,103	$ 710,585
Derivative liabilities	4,897,066	9,826,759
Convertible notes at fair value	1,745,305	2,855,709
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Derivative liabilities
Convertible notes at fair value
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Derivative liabilities	4,897,066	9,826,759
Convertible notes at fair value
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	200,103	710,585
Derivative liabilities
Convertible notes at fair value	$ 1,745,305	$ 2,855,709

SUMMARY OF CHANGES IN FAIR VALU

SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS (Details) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Beginning balance		$ 710,585	$ 189,543
Purchases and issuances		100,000	590,885
Loss (gain) from change in fair value (1)	[1]	(610,482)	(69,843)
Ending balance		200,103	710,585
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Beginning balance		2,855,709	1,832,439
Purchases and issuances			132,000
Day one loss on value of hybrid instrument (1)	[2]		2,042,612
Repayments in cash		(45,000)	(40,480)
Conversion to common stock		(36,000)	(2,344,399)
Loss (gain) from change in fair value (1)	[2]	(1,029,404)	1,233,538
Ending balance		$ 1,745,305	$ 2,855,709
[1]The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.[2]The losses (gains) related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

SUMMARY OF ASSUMPTIONS AND THE

SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS (Details) - Convertible Notes Payable [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) Day $ / shares	Dec. 31, 2021 USD ($) Day $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Face Amount | $	$ 711,446	$ 762,446
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.00040	$ 0.00050
Percentage of stock price for look-back period	50%	50%
Look-back period | Day	3	3
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.00048	$ 0.00097
Percentage of stock price for look-back period	60%	60%
Look-back period | Day	25	25
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	8	8
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	10	10
Measurement Input, Default Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	0.20	0.20
Measurement Input, Default Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	0.24	0.24

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details Narrative)	Sep. 30, 2022
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	2.79
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	3.92
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	411

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw Materials	$ 131,005	$ 126,349
Finished Goods	8,721	3,820
Total Inventories	139,726	130,169
Less: Long-term inventory	(90,380)	(98,880)
Current portion	$ 49,346	$ 31,289

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total	$ 324,879	$ 266,886
Less: Accumulated depreciation	(239,273)	(222,185)
Property and equipment, net	85,606	44,701
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	25,120	25,120
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	34,757	34,757
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	162,557	104,564
Telephone Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	12,421	12,421
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	16,856	16,856
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 73,168	$ 73,168

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 5,898	$ 2,793	$ 17,088	$ 6,178

DUE TO_FROM OFFICER (Details Na

DUE TO/FROM OFFICER (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Due to officers or stockholders, current	$ 61,439		$ 61,439		$ 199,726
Repayments of related party debt			204,000	$ 120,250
Proceeds from related party debt			62,201	56,900
Accrued interest on the demand			3,512	5,788	7,520
Accounts Receivable, Credit Loss Expense (Reversal)	(21,799)	$ (35,000)		38,000
Accounts Receivable, Credit Loss Expense (Reversal)	21,799	35,000		$ (38,000)
[custom:ProvisionForDoubtfulAccountsBadDebtRecovery]		$ 35,000
Rik Deitsch [Member]
Defined Benefit Plan Disclosure [Line Items]
Due to officers or stockholders, current	$ 61,439		$ 61,439		$ 199,726
Debt instrument, interest rate, stated percentage	4%		4%		4%
Repayments of related party debt			$ 204,000		$ 182,741
Proceeds from related party debt			62,201		$ 105,780
Accrued interest on the demand			$ 3,512

SCHEDULE OF DEBT (Details)

SCHEDULE OF DEBT (Details) - USD ($)	Sep. 30, 2022	Aug. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes payable – Unrelated third parties (Net of discount of $19,106 and $0, respectively) (2)	$ 1,285,287	$ 166,926	$ 1,135,257
Convertible notes payable – Unrelated third parties (Net of discount of $183,570 and $283,429, respectively) (3)	4,609,567		3,751,760
Convertible notes payable, at fair value (4)	1,745,305		2,855,709
Other advances from an unrelated third party (5)	225,000		225,000
SBA notes payable(6)	149,900		149,900
Ending balances	8,015,059		8,117,626
Less: Long-term portion-Convertible Notes payable-Unrelated third parties	(4,707)		(369,401)
Less: Long-term portion- SBA notes payable	(146,970)		(146,970)
Current portion	$ 7,863,382		$ 7,600,446

SCHEDULE OF DEBT (Details) (Par

SCHEDULE OF DEBT (Details) (Parenthetical) - USD ($)	Sep. 30, 2022	Aug. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Debt instrument unamortized discount		$ 16,693
Note Payable [Member]
Short-Term Debt [Line Items]
Debt instrument unamortized discount	$ 19,106		$ 0
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument unamortized discount	$ 183,570		$ 283,429

SCHEDULE OF FUTURE MINIMUM PRIN

SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Current portion	$ 7,863,382	$ 7,600,446
PPP and EIDL Loan [Member]
Short-Term Debt [Line Items]
2022(2 months remaining)	525
2023	3,222
2024	3,345
2025	3,472
2026	3,605
Thereafter	135,731
Total	149,900
Less: Long-term portion - SBA notes payable	(146,970)
Current portion	$ 2,930

DEBTS (Details Narrative)

DEBTS (Details Narrative)							1 Months Ended																																					2 Months Ended	3 Months Ended								5 Months Ended	8 Months Ended	9 Months Ended		12 Months Ended
	Jan. 02, 2022 USD ($)	Oct. 22, 2020 USD ($)	Feb. 28, 2019 USD ($) $ / shares shares	Feb. 15, 2019 USD ($)	Sep. 26, 2016 USD ($)	Aug. 02, 2011 USD ($) shares	Aug. 31, 2022 USD ($) $ / shares shares	May 31, 2022 USD ($) $ / shares shares	Feb. 28, 2022 USD ($) shares	Jan. 31, 2022 USD ($) $ / shares shares	Aug. 31, 2021 USD ($) $ / shares shares	Apr. 30, 2021 USD ($) shares	Mar. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares	Nov. 30, 2020 USD ($) shares	Oct. 31, 2020 USD ($)	Sep. 30, 2020 USD ($) shares	Aug. 31, 2020 USD ($)	Jul. 31, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($)	May 31, 2020 USD ($)	Apr. 30, 2020 USD ($)	Mar. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($) $ / shares shares	Nov. 30, 2019 USD ($)	Jun. 30, 2019 USD ($) shares	May 31, 2019 USD ($) shares	Feb. 28, 2019 USD ($) $ / shares	Jan. 31, 2019 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Nov. 30, 2017 USD ($) shares	Oct. 31, 2017 USD ($)	Jul. 31, 2017 USD ($)	Jun. 30, 2017 USD ($)	May 31, 2017 USD ($) Day	Apr. 30, 2017 USD ($) shares	Oct. 31, 2016 USD ($)	Aug. 31, 2016 USD ($) shares	May 31, 2016 USD ($)	Apr. 30, 2016 USD ($)	Aug. 31, 2013 USD ($)	Jun. 30, 2012 USD ($)	Feb. 29, 2020 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares	Mar. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($) $ / shares	Mar. 31, 2020 USD ($)	Mar. 31, 2012 USD ($)	Jun. 30, 2021 USD ($) shares	Nov. 01, 2021	Sep. 30, 2022 USD ($) Day $ / shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) Day $ / shares shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) $ / shares	Dec. 31, 2012 USD ($)	Dec. 31, 2010 USD ($)	Jun. 30, 2022 USD ($) $ / shares	Nov. 30, 2021 USD ($) $ / shares	Aug. 31, 2018 USD ($)	Jul. 31, 2018 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2011 USD ($)
Short-Term Debt [Line Items]
Accrued interest																																													$ 145,508		$ 147,768								$ 145,508		$ 147,768
Notes payable							$ 166,926																																						1,285,287		1,135,257								1,285,287		1,135,257
Debt discount							16,693
Debt instrument periodic payament							$ 3,000
Payments for rent								$ 5,000																																					10,000										10,000
Shares issued, shares | shares							500,000
Shares issued, value							$ 500
Debt discount																																																							404,549	$ 232,117
Convertible notes payable																																													4,609,567		3,751,760								4,609,567		3,751,760
Proceeds from convertible debt							17,250																																																710,000	1,976,560
Repayments of notes payable																								$ 13,500
Repayments of convertible debt							3,000				$ 16,693																																												60,994	65,028
Stock issued																																																							36,000	2,344,399
Gain (Loss) on Extinguishment of Debt																																																$ (56,339)							(151,559)	(485,836)
Other expense							500
Convertible notes at fair value																																													1,745,305		2,855,709								1,745,305		2,855,709
Other advances from an unrelated third party																																													$ 225,000		$ 225,000								225,000		$ 225,000
Long term debt																																																							$ 251,340
Maximum [Member]
Short-Term Debt [Line Items]
Warrants at an exercise price | $ / shares																																													$ 0.002		$ 0.002								$ 0.002		$ 0.002
Minimum [Member]
Short-Term Debt [Line Items]
Warrants at an exercise price | $ / shares																																													0.001		0.001								0.001		0.001
Convertible Notes Payable [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Conversion Price | $ / shares																																													0.00048		0.00097								$ 0.00048		$ 0.00097
Trading days | Day																																																							25		25
Conversion percentage																																																							60%		60%
Convertible Notes Payable [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Conversion Price | $ / shares																																													$ 0.00040		$ 0.00050								$ 0.00040		$ 0.00050
Trading days | Day																																																							3		3
Conversion percentage																																																							50%		50%
Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount			$ 37,917																									$ 37,917
Debt conversion, converted instrument, shares issued | shares																										750,000,000	750,000,000																	500,000,000
Debt Instrument Unamortized Discount Premium																										$ 40,000
Debt discount																										$ 4,688
Restricted Stock | shares																										16,000,000
Convertible Notes Payable																										$ 240,000																			$ 240,000		$ 240,000								$ 240,000		$ 240,000
Derivative Loss																										240,000
Debt Conversion, Original Debt, Amount																										100,000	$ 100,000																	$ 175,000
Debt conversion, converted instrument amount																										$ 275,000	275,000																	$ 425,000
Debt instrument, description																										The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion
Convertible Promissory Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount			$ 1,000,000																									$ 1,000,000
Conversion Price | $ / shares			$ 0.0005																									$ 0.0005
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													275,000		275,000								275,000		275,000
Convertible Notes Payable [Member] | Eight Tranches [Member]
Short-Term Debt [Line Items]
Notes payable														$ 20,199										372,374																																		$ 20,199	$ 372,374
Convertible Notes Payable [Member] | Tranche [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													27,000										27,000
Notes payable																																													132,000										132,000
Debt instrument accrued interest																																														$ 11,412
Repayments of convertible debt																																																							45,000		40,480
Derivative Loss																																															2,042,612										2,042,612
University Centre West Ltd [Member]
Short-Term Debt [Line Items]
Payments for rent																																																													$ 55,410
Non Related Party Ten [Member]
Short-Term Debt [Line Items]
Notes payable																																													74,000		74,000								74,000		74,000
Non Related Party Elven [Member] | Note Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable																																$ 18,000
Debt Instrument Unamortized Discount Premium																																3,000
Future Receipts Agreement [Member]
Short-Term Debt [Line Items]
Notes payable																																													87,000										87,000
Non-related Party [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													12,629		12,629								12,629		12,629
Interest Rate																																				20%
Debt maturity date																																				May 04, 2018
Debt instrument accrued interest																																																							16,728		14,834
Debt instrument convertible debt percentage																																				60%
Convertible Notes Payable																																				$ 64,000									48,929		70,418								48,929		70,418
Trading days | Day																																				20
Non-related Party [Member] | Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Interest Rate		8%
Debt instrument accrued interest		$ 250,000
Note Holder [Member] | Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount		509,301
Debt instrument accrued interest		$ 234,417
Derivative Loss																																													286,969										286,969
Non Related Party Twenty Two [Member] | Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													17,829		17,829								17,829		17,829
Unrelated Third Party [Member]
Short-Term Debt [Line Items]
Other advances from an unrelated third party																																													225,000		225,000								225,000		225,000
Unrelated Third Party [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													37,917		88,917								37,917		88,917
Convertible Notes Payable																																													75,834		355,668								75,834		355,668
Brewer and Associates Consulting, LLC [Member] | Non Related Party Twenty [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													20,000		20,000								20,000		20,000
Debt instrument accrued interest																																																							24,217		21,183
Debt instrument convertible debt percentage																																																																				55%
Convertible Notes Payable																																													80,395		84,768								80,395		84,768
Note Payable [Member]
Short-Term Debt [Line Items]
Debt discount																																													19,106		0								19,106		0
Promissory Note One [Member]
Short-Term Debt [Line Items]
Interest Rate																																									10%
Accrued interest																																													6,541		5,783								6,541		5,783
Proceeds from issuance of debt																																									$ 10,000
Promissory Note Two [Member]
Short-Term Debt [Line Items]
Interest Rate																																								2%
Accrued interest																																													83,434		74,334								83,434		74,334
Notes payable																																													50,000		50,000								50,000		50,000
Proceeds from issuance of debt																																								$ 75,000
Shares issued, shares | shares																																					5,000,000
Repayments of notes payable																																					$ 25,000
Promissory Note Three [Member]
Short-Term Debt [Line Items]
Interest Rate																																																																			2%
Accrued interest																																													76,634		67,534								76,634		67,534
Notes payable																																													50,000		50,000								50,000		50,000										$ 50,000
Promissory Note Four [Member]
Short-Term Debt [Line Items]
Interest Rate																																							2%
Notes payable																																													333,543		333,543								333,543		333,543
Proceeds from issuance of debt																																							$ 333,543
Interest payable																																													248,378		187,673								248,378		187,673
Promissory Note Four [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Debt discount																	$ 5,895
Stock issued, reverse stock splits | shares																	10,000,000
Shares issued, shares | shares																																							20,000,000
Shares issued, value																	$ 6,000
Promissory Note Five [Member]
Short-Term Debt [Line Items]
Interest Rate					10%
Accrued interest																													$ 15,900																1,371		1,371								1,371		1,371
Notes payable																													60,000																15,000		15,000								15,000		15,000
Proceeds from issuance of debt					$ 75,000
Debt settlement amount																															$ 15,000
Promissory Note Six [Member]
Short-Term Debt [Line Items]
Interest Rate																																						2%
Accrued interest																																													72,934		63,834								72,934		63,834
Proceeds from issuance of debt																																						$ 50,000
Promissory Note Seven [Member]
Short-Term Debt [Line Items]
Interest Rate																																			10%
Accrued interest																																													6,698		5,750								6,698		5,750
Proceeds from issuance of debt																																			$ 12,500
Promissory Note Eight [Member]
Short-Term Debt [Line Items]
Interest Rate																																		15%
Notes payable																																													33,874		33,874								33,874		33,874
Proceeds from issuance of debt																																		$ 200,000
Debt settlement amount																																																							33,874
Repayment of debt settlement amount																																																		$ 130,401
Repayment of debt																																																		14,376								44,478	42,698	$ 34,976
Promissory Note Eight [Member] | One Unrelated Third Parties [Member]
Short-Term Debt [Line Items]
Debt settlement amount																														$ 130,401
Repayment of debt																														5,000
Promissory Note Eight [Member] | Two Unrelated Third Parties [Member]
Short-Term Debt [Line Items]
Debt settlement amount																														40,000
Repayment of debt																														$ 2,000
Promissory Note Nine [Member]
Short-Term Debt [Line Items]
Notes payable																																													50,000		50,000								50,000		50,000
Debt discount																																		10,000
Proceeds from issuance of debt																																		$ 50,000
Promissory Note Twelve [Member]
Short-Term Debt [Line Items]
Debt discount																																20,000
Proceeds from issuance of debt																																$ 120,000
Debt settlement amount																							$ 50,000
Shares issued, shares | shares																							125,000,000									10,000,000
Shares issued, value																							$ 87,500									$ 32,200
Settlement of debt																							$ 37,500
Debt conversion, converted instrument, shares issued | shares																																36,000,000
Debt instrument unamortized discount																																$ 14,000
Convertible Debt																																																																				$ 74,000
Promissory Note [Member]
Short-Term Debt [Line Items]
Notes payable									$ 183,619																																				60,000		60,000								60,000		60,000
Debt discount							16,693		16,693
Repayment of debt							$ 183,619
Shares issued, shares | shares							10,000,000				20,866,250
Shares issued, value							$ 10,000				$ 54,252
Origination fees																																																							29,685
Restricted Stock | shares							10,000,000
Gain (Loss) on Extinguishment of Debt							$ 10,000	114,000			37,559
Promissory Note [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																													75,000																55,900		55,900								55,900		55,900
Interest payable																													15,900
Convertible Notes Payable																													60,000																111,800		156,000								111,800		156,000
Derivative Loss																													75,900
Promissory Note [Member] | Non Related Party Ten [Member] | Note Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable																	70,000
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													4,609,567		3,751,760								4,609,567		3,751,760
Debt discount																																													183,570		283,429								183,570		283,429
Debt instrument unamortized discount																																													183,570		283,429								183,570		283,429
Debt discount																																													123,813			91,455							388,994	213,924
Debt discount																																													183,570		283,430								183,570		283,430
Convertible Notes Payable, Current																																													3,125,268										3,125,268
Convertible Notes Payable [Member] | Unrelated Third Party [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																																																$ 286,550
Debt Instrument, Term																																																						1 year
Debt discount																																																																$ 26,050
Debt discount																																																							0		13,070
Conversion Price | $ / shares																																																																$ 0.01
Promissory Note Thirteen [Member]
Short-Term Debt [Line Items]
Debt discount																																	$ 10,000
Proceeds from issuance of debt																																	$ 60,000
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Debt discount																$ 9,200								$ 62,950																																			62,950	62,950
Shares issued, shares | shares																								800,000,000
Shares issued, value																								$ 87,100
Convertible Debt																55,000
Debt discount																																																											28,421
Proceeds from convertible debt																																																												618,250
Debt discount																																																												$ 255,655
Convertible Notes Payable One [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Excerice of price | shares			128,400
Warrants at an exercise price | $ / shares			$ 0.001																									$ 0.001
Fair value adjustment of warrants																$ 36,300,000		$ 92,100,000																																					541		195,178
Convertible Notes Payable One [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument convertible price | $ / shares																																																												$ 0.0003
Convertible Notes Payable One [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument convertible price | $ / shares																																																												$ 0.001
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable														287,400			$ 268,200																																									287,400
Debt discount			$ 5,000					15,000		$ 15,000				53,600					$ 7,500									$ 5,000																				70,350	$ 112,725				$ 112,725			70,350		53,600
Repayment of debt																			22,000
Shares issued, value																			700
Convertible Debt								$ 115,000		115,000									$ 57,500
Debt discount																																																										83,720
Proceeds from convertible debt																												$ 55,000																			358,800		864,225									555,600
Debt discount														1,276,902																																												1,276,902
Conversion Price | $ / shares			$ 0.0005																									$ 0.0005
Convertible Notes Payable, Current														$ 101,448																																												101,448
Convertible Notes Payable Two [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Excerice of price | shares								222,500,000
Convertible Notes Payable Two [Member] | Valuation Technique, Option Pricing Model [Member]
Short-Term Debt [Line Items]
Debt discount								$ 100,000		$ 100,000
Convertible Notes Payable Two [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Excerice of price | shares								164,285,714		164,285,714									71,875,000
Warrants at an exercise price | $ / shares								$ 0.002		$ 0.002									$ 0.002
Fair value adjustment of warrants																																																							0		106,032
Convertible Notes Payable Two [Member] | Warrant [Member] | Valuation Technique, Option Pricing Model [Member]
Short-Term Debt [Line Items]
Debt discount								$ 15,000		$ 15,000
Fair value adjustment of warrants																																																							93,748
Two Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Debt discount																											$ 6,400
Two Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable																								17,370																																			17,370
Debt discount			$ 14,500																					14,500	$ 14,500			$ 14,500																															14,500
Debt discount																								17,370
Proceeds from convertible debt																								$ 174,500	$ 174,500			$ 174,500
Debt instrument convertible price | $ / shares														$ 0.0002										$ 0.000275
Debt instrument convertible price | $ / shares														$ 0.0008										$ 0.0002
Debt discount																								$ 736,180																																			$ 736,180
Repayments of convertible debt																								$ 10,000
Restricted Stock | shares																			1,000,000
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Debt maturity date	Aug. 29, 2022
Notes payable	$ 228,563
Debt discount													$ 93,609	$ 50,000																																	$ 46,800			93,609							46,800	50,000
Proceeds from convertible debt																																																539,351		$ 717,667
Debt instrument convertible price | $ / shares																																															$ 0.0003
Debt instrument convertible price | $ / shares																																															$ 0.002
Convertible Notes Payable Three [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt discount														$ 7,500																																												$ 7,500
Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Debt discount																																															$ 22,500										22,500
Proceeds from convertible debt																																																									172,500
Convertible Notes Payable Four [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt discount																																															$ 150,000										$ 150,000
Excerice of price | shares																																																									246,428,571
Warrants at an exercise price | $ / shares																																															$ 0.002										$ 0.002
Fair value adjustment of warrants																																																							105,814		$ 409,374
Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													15,433		$ 22,677								15,433		22,677
Interest Rate													12%																																					12%
Interest expense																																													513			793							$ 1,756	1,951
Notes payable													$ 30,000																																					$ 30,000
Repayment of debt													7,323																																7,244
Debt instrument periodic payament													$ 1,000
Shares issued, shares | shares												2,000,000
Conversion Price | $ / shares													$ 0.01																																					$ 0.01
Convertible Notes Payable Six [Member]
Short-Term Debt [Line Items]
Debt Instrument, Fair Value								222,500				$ 15,200
Debt settlement amount												8,500	$ 6,000
Shares issued, shares | shares													11,000,000
Shares issued, value													$ 104,500
Settlement of debt								114,000				11,200	98,500
Proceeds from convertible debt												12,000	11,000
Repayments of convertible debt												4,500	5,000
Stock issued								108,500				$ 4,000	6,000
Convertible Notes Payable Seven [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount											183,619
Notes payable								108,500			166,926																																																				$ 5,750
Debt discount											$ 16,693
Conversion Price | $ / shares							$ 0.002				$ 0.002
Promissory Note Eleven [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount									16,693		$ 16,693
Debt Instrument, Fair Value									$ 54,252
Debt settlement amount								$ 108,500			$ 166,926
Conversion Price | $ / shares											$ 0.002
Loss on settlement of debt											$ 37,559
Promissory Note Eleven [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Shares issued, shares | shares									20,866,250
Convertible Loans One [Member]
Short-Term Debt [Line Items]
Notes payable																																																																				20,000
Convertible Debt																																																																				$ 120,000
Convertible Loans Four [Member]
Short-Term Debt [Line Items]
Interest Rate Terms																																																							We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date
Convertible Debtentures [Member] | Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Notes payable																																													50,000		50,000								$ 50,000		50,000
Debt instrument accrued interest																																																							42,367		33,490
Convertible Notes Payable																																													167,940		202,491								167,940		202,491
Convertible Debtentures [Member] | Non-related Party [Member] | Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Interest Rate																																																																		8%
Debt instrument convertible debt percentage																																																																		24%
Convertible Notes Payable																																																																		$ 50,000
Derivative Loss																																																																		$ 46,734
Convertible Debtentures [Member] | Note Holder [Member]
Short-Term Debt [Line Items]
Debt instrument accrued interest																																																							82,022		32,657
Convertible Notes Payable																																													714,044		946,639								714,044		946,639
Convertible Debtentures [Member] | Non Related Party Twenty Two [Member] | Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													20,000		20,000								20,000		20,000
Interest Rate																																																																	8%
Notes payable																																																																	$ 20,000
Debt instrument accrued interest																																																							16,500		12,923
Debt instrument convertible debt percentage																																																																	24%
Convertible Notes Payable																																													66,363		79,815								66,363		79,815
Restatement of Promissory Notes [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Repayments of convertible debt																													75,900
Restricted Stock | shares															100,000,000
Convertible Notes Payable															$ 20,000														$ 75,900
Conversion percentage																													50%
Stock issued during period, restricted stock value															140,000
Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Repayment of debt							$ 17,250
Shares issued, value							$ 500
Restricted Stock | shares							500,000
Convertible Promissory Note [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt Instrument, Fair Value																																													480,000		960,000								480,000		960,000
PPP and EIDL Loan [Member]
Short-Term Debt [Line Items]
Accrued Interest																																													13,124		8,906								13,124		8,906
Loan Agreement [Member] | Note Payable One [Member]
Short-Term Debt [Line Items]
Debt Instrument, Term																																																														9 months
Settlement Agreement [Member] | Non Related Party Elven [Member] | Note Payable Two [Member]
Short-Term Debt [Line Items]
Repayments of notes payable																																																							18,000		18,000
Debt instrument accrued interest																																																							2,000		2,000
Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Short-Term Debt [Line Items]
Notes payable																																																																					$ 175,000
Repayment of debt						$ 350,000																																														$ 25,000
Debt instrument periodic payament						$ 50,000
Penalty for non-payment																																																																					$ 25,000
Sale of stock, shares | shares						142,858
Stock issued, reverse stock splits | shares						5,714,326
Proceeds from settlement						$ 450,000
Proceeds from initial legal settlement						350,000
Penalties on legal settlement						$ 100,000
Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member] | Note Payable Two [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													2,675										2,675
Debt discount																																													130,977										130,977
Repayment of debt																																$ 10,000																							68,023
Settlement Agreement [Member] | Southridge Partners LLP [Member]
Short-Term Debt [Line Items]
Business combination, consideration transferred																																										$ 281,772	$ 281,772
Future Receipts Agreement [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													16,431										16,431
Future Receipts Agreement [Member] | Note Payable Two [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																																															60,000
Debt discount																																													31,730										31,730
Repayment of debt																																																							38,839
Future Receipts Agreement [Member] | Promissory Note [Member]
Short-Term Debt [Line Items]
Debt discount																																													12,369										885
Note Agreement [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt Instrument, Fair Value									$ 36,000																																								$ 2,344,399				$ 2,344,399
Restricted Stock | shares									12,000,000																																												240,350,000
Stock issued during period, restricted stock value									$ 6,000																																												$ 120,175
SBA Loan Agreement [Member]
Short-Term Debt [Line Items]
Interest Rate																	3.75%			3.75%
Repayments of convertible debt																				$ 5,000		$ 5,000
Debt Conversion, Original Debt, Amount																				731		731
Outstanding notes payable																				$ 150,000		$ 150,000
SBA Loan Agreement [Member] | PPP [Member]
Short-Term Debt [Line Items]
Interest Rate																					1%
Debt instrument, description																					During May 2020, we entered into a two-year loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $64,895 with an annual interest rate of one percent (1%), with a term of twenty-four (24) months, whereby a portion of the loan proceeds have been used for certain labor costs, office rent costs and utilities, which may be subject to a loan forgiveness, pursuant to the terms of the SBA/PPP program. We used the proceeds primarily for payroll costs. The entire loan was forgiven in November 2021
Long term debt																					$ 64,895
Director [Member]
Short-Term Debt [Line Items]
Accrued interest													$ 40,000																																	15,000	10,000			$ 40,000							10,000						15,000
Director [Member] | Loan Agreement [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																																														$ 200,000
Interest Rate Terms																																																														interest calculated at 10% for the first month plus 12% after 30 days from funding
Interest Rate																																																														12%
Debt maturity date																																																														Dec. 31, 2016
Accrued interest																																													145,508		147,768								145,508		147,768
Interest expense																																													4,272			$ 4,504							12,740	$ 13,881
Former Director [Member] | Two Promissory Notes [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount				$ 101,818
Interest Rate																																							12%
Accrued interest				21,023																																									60,037		51,856								60,037		51,856
Notes payable																																													91,156		$ 91,156								$ 91,156		$ 91,156
Proceeds from issuance of debt																																							$ 200,000
Debt Instrument, Fair Value																																							$ 100,000
Debt settlement amount				$ 104,000																																															$ 88,500
Gain on settlement of debt																																																			$ 15,500
Repayment of debt settlement amount															$ 88,500
Debt settlement, description																																																							The remaining principal balance of $91,156 and accrued interest of $60,037 is being disputed in court and negotiation for settlement
Non-related Party [Member] | Promissory Note [Member]
Short-Term Debt [Line Items]
Interest Rate										63.76%
Due from related parties										$ 199,000
Origination fees										$ 4,975
Debt discount																																													850										$ 2,300
Future Receipts Agreement [Member] | Promissory Note [Member]
Short-Term Debt [Line Items]
Due from related parties																																																															87,000
Unrelated Third Parties [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount																																													264,500	172,500									264,500								379,500
Debt discount																																													$ 34,500	$ 22,500									$ 34,500								$ 49,500
Unrelated Third Parties [Member] | Convertible Notes Payable [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Conversion Price | $ / shares																																													$ 0.0006	$ 0.0008									$ 0.0006								$ 0.0008
Unrelated Third Parties [Member] | Convertible Notes Payable [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Conversion Price | $ / shares																																													$ 0.0005	$ 0.0005									$ 0.0005								$ 0.0006

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)			1 Months Ended								3 Months Ended		5 Months Ended	9 Months Ended
	Nov. 15, 2021	Oct. 30, 2017	Aug. 31, 2022	May 31, 2022	Feb. 28, 2022	Aug. 31, 2021	Jul. 31, 2021	Apr. 30, 2021	Mar. 31, 2021	Jul. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Jan. 31, 2022	Dec. 31, 2021	Nov. 30, 2021	Nov. 18, 2021	Nov. 17, 2021	Dec. 31, 2020	Sep. 30, 2020	Feb. 28, 2019
Class of Stock [Line Items]
Common stock, shares authorized											12,000,000,000			12,000,000,000				12,000,000,000		12,000,000,000	8,000,000,000
Stock issued during period, shares, new issues			500,000
Share Price											$ 0.133			$ 0.133
Debt instrument unamortized discount			$ 16,693
Notes payable			166,926								$ 1,285,287			$ 1,285,287				$ 1,135,257
Stock issued during period, value, new issues			$ 500
Gain (Loss) on extinguishment of debt												$ (56,339)		(151,559)	$ (485,836)
Stock issued														36,000	2,344,399
Issuance of common stock in exchange for services to consultants												117,000			150,000
Stock based compensation											0	$ 64,750		20,500	$ 66,195
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common stock in exchange for services to consultants, shares												20,000,000			25,000,000
Issuance of common stock in exchange for services to consultants												$ 20,000			$ 25,000
Promissory Note [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues			10,000,000			20,866,250
Stock issued during period, restricted stock shares			10,000,000
Debt instrument unamortized discount			$ 16,693		$ 16,693
Notes payable					$ 183,619						60,000			60,000				60,000
Stock issued during period, value, new issues			10,000			$ 54,252
Gain (Loss) on extinguishment of debt			10,000	$ 114,000		37,559
Repayment of debt			$ 183,619
Convertible Notes Payable Seven [Member]
Class of Stock [Line Items]
Debt instrument unamortized discount						16,693
Notes payable				108,500		$ 166,926										$ 5,750
Convertible Notes Payable Two [Member]
Class of Stock [Line Items]
Debt instrument unamortized discount				$ 15,000						$ 7,500		$ 70,350	$ 112,725		$ 70,350		$ 15,000					$ 53,600		$ 5,000
Notes payable																						$ 287,400	$ 268,200
Stock issued during period, value, new issues										700
Repayment of debt										$ 22,000
Convertible Notes Payable Two [Member] | Common Stock [Member]
Class of Stock [Line Items]
Excerice of price				222,500,000
Convertible Notes Payable Six [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues									11,000,000
Stock issued during period, value, new issues									$ 104,500
Stock issued				$ 108,500				$ 4,000	$ 6,000
Debt instrument fair value				$ 222,500				$ 15,200
Convertible Promissory Note [Member]
Class of Stock [Line Items]
Stock issued during period, restricted stock shares			500,000
Stock issued during period, value, new issues			$ 500
Repayment of debt			$ 17,250
Convertible Notes Payable [Member] | Convertible Promissory Note [Member]
Class of Stock [Line Items]
Debt instrument fair value											480,000			480,000				$ 960,000
Convertible Notes Payable [Member] | Note Agreement [Member]
Class of Stock [Line Items]
Stock issued during period, restricted stock shares					12,000,000								240,350,000
Stock issued during period, restricted stock value					$ 6,000								$ 120,175
Debt instrument fair value					36,000								$ 2,344,399
Note Holder [Member]
Class of Stock [Line Items]
Fair value of debt converted					$ 36,000
Note Holder [Member] | Restricted Stock [Member]
Class of Stock [Line Items]
Stock issued during period, restricted stock shares					12,000,000
Consultant [Member]
Class of Stock [Line Items]
Issuance of common stock in exchange for services to consultants, shares							5,000,000
Issuance of common stock in exchange for services to consultants							$ 41,000
Stock based compensation											$ 0			$ 20,500
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		20,000,000
Stock issued during period, shares, new issues		3,000,000
Series A Preferred Stock [Member] | Board of Directors [Member]
Class of Stock [Line Items]
Stock issued during period shares exchanged	3,000,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized											20,000,000			20,000,000				20,000,000
Stock issued during period, shares, new issues									12,000,000
Preferred stock, par value									$ 0.001		$ 0.001			$ 0.001				$ 0.001
Preferred stock liquidation value											$ 0			$ 0				$ 0
Shares issued																			9,000,000
Accrued salaries																			$ 540,000
Series B Preferred Stock [Member] | Board of Directors [Member]
Class of Stock [Line Items]
Stock issued during period shares exchanged	3,000,000

SCHEDULE OF WARRANTS ISSUED (De

SCHEDULE OF WARRANTS ISSUED (Details) - shares	1 Months Ended
	Oct. 31, 2020	Aug. 31, 2020
Share-Based Payment Arrangement [Abstract]
Number of Warrants	36,300,000	92,100,000
Month of Expiration	October, 2022	August, 2022

SUMMARY OF WARRANTS OUTSTANDING

SUMMARY OF WARRANTS OUTSTANDING (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Weighted Average Exercise Price, Warrants, Beginning	$ 0.0017
Weighted Average Exercise Price, Warrants, Ending	$ 0.0019	$ 0.0017
Warrant [Member]
Number of warrants outstanding, Beginning	446,703,571	202,775,000
Weighted Average Exercise Price, Warrants, Beginning	$ 0.0017	$ 0.0017
Number of warrants, Exercised
Weighted Average Exercise Price, Warrants, Exercised
Number of warrants, Issued	164,285,714	410,403,571
Weighted Average Exercise Price, Warrants, Issued	$ 0.0020	$ 0.0014
Number of warrants, Expired	(163,975,000)	(166,475,000)
Weighted Average Exercise Price, Warrants, Expired	$ 0.0014	$ 0.0015
Number of warrants outstanding, Ending	447,014,285	446,703,571
Weighted Average Exercise Price, Warrants, Ending	$ 0.0019	$ 0.0017

SUMMARY OF FIXED PRICE WARRANTS

SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Number Outstanding	447,014,285	446,703,571
Weighted Average Contractual Life	3 months 18 days	8 months 1 day
Weighted Average Exercise Price	$ 0.0019	$ 0.0017
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	0.001	0.001
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	$ 0.002	$ 0.002

STOCK WARRANTS (Details Narrati

STOCK WARRANTS (Details Narrative) - USD ($)	2 Months Ended	5 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	May 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Aug. 31, 2022	Oct. 31, 2020	Aug. 31, 2020
Short-Term Debt [Line Items]
Debt instrument unamortized discount					$ 16,693
Two Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Warrants, fair value			$ 0	$ 106,032
Two Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument unamortized discount	$ 7,500
Warrants price	$ 0.002
Equity instruments other than options, grants in period	71,875,000
Long-term debt, gross	$ 57,500
Three Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount				172,500
Debt instrument unamortized discount				$ 22,500
Warrants price				$ 0.002
Warrants, fair value			105,814	$ 409,374
Excerice of price				246,428,571
Four Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount		$ 115,000
Debt instrument unamortized discount		$ 15,000
Warrants price		$ 0.002
Warrants, fair value			$ 93,748
Excerice of price		164,285,714
Warrant [Member]
Short-Term Debt [Line Items]
Warrants price			$ 0.0008
Excerice of price			164,285,714	410,403,571
Number of warrants			$ 0
Warrant [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount						$ 16,500	$ 38,500
Debt instrument unamortized discount						$ 1,650	$ 7,550
Warrants price							$ 0.001
Warrants, fair value			$ 541	$ 195,178
Money Warrants [Member]
Short-Term Debt [Line Items]
Number of warrants to purchase common stock			0

SCHEDULE OF ACCRUED EXPENSES (D

SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued consulting fees	$ 161,550	$ 161,550
Accrued payroll taxes	227,912	215,543
Accrued interest	571,151	469,040
Accrued others	2,913	5,337
Total	$ 963,526	$ 851,470

SCHEDULE OF PREPAID EXPENSES (D

SCHEDULE OF PREPAID EXPENSES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expenses
Supplier advances for future purchases	$ 339,162	$ 294,162
Reserve for supplier advances	(294,162)	(294,162)
Net supplier advances	45,000
Prepaid professional fees	72,650	65,650
Deferred stock compensation		20,500
Total	$ 117,650	$ 86,150

PREPAID EXPENSES (Details Narra

PREPAID EXPENSES (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expenses
Future reserve for purchases	$ 0	$ 48,000
Total valuation allowance for prepaid	$ 294,162	$ 294,162

CONVERTIBLE NOTES RECEIVABLE (D

CONVERTIBLE NOTES RECEIVABLE (Details Narrative) - USD ($)	3 Months Ended		8 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Nov. 01, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Aug. 31, 2022	Nov. 30, 2021
Short-Term Debt [Line Items]
Debt original issuance discount							$ 16,693
Convertible notes receivable repayments	$ 50,250			$ 50,250
Amortization of notes receivables				404,549	232,117
Convertible notes receivable	270,896			270,896		$ 273,480
Other Income [Member]
Short-Term Debt [Line Items]
Amortization of notes receivables	4,210	$ 4,750		16,215	6,465
Amount of debt expired				268,750
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible notes	4,609,567			4,609,567		3,751,760
Debt original issuance discount	183,570			183,570		283,429
Amortization of notes receivables	123,813	$ 91,455		388,994	$ 213,924
Convertible Notes Payable [Member] | Unrelated Third Party [Member]
Short-Term Debt [Line Items]
Convertible notes								$ 286,550
Debt original issuance discount								$ 26,050
Debt instrument, convertible, conversion Price								$ 0.01
Debt term			1 year
Amortization of notes receivables				0		$ 13,070
Convertible Notes Payable [Member] | Third Party [Member]
Short-Term Debt [Line Items]
Convertible notes	34,596			34,596
Debt original issuance discount	$ 3,145			$ 3,145
Debt instrument, convertible, conversion Price	$ 0.01			$ 0.01

SCHEDULE OF LEASE COST AND BALA

SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 60,297	$ 80,396
Short-term lease cost
Total lease cost	60,297	80,396
Operating ROU Assets	43,397	93,811
Operating lease obligations, current portion	20,003	77,673
Operating lease obligations, non-current portion
Total	$ 20,003	$ 77,673
Weighted average remaining lease term (in years) - operating leases	3 months	1 year
Weighted average discount rate-operating leases	8%	8%
Cash paid for amounts included in the measurement of operating lease liabilities	$ 67,553	$ 95,846

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
2022 (Remaining three months)	$ 20,270
Total future lease payments	20,270
Less imputed interest	267
Total	$ 20,003	$ 77,673

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)				1 Months Ended			9 Months Ended		12 Months Ended
	Oct. 12, 2018	Aug. 01, 2017	Jul. 31, 2015	Aug. 31, 2022	Feb. 28, 2021	Oct. 31, 2015	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Common stock shares issued							7,596,852,214		7,330,985,964	1,000,000
Note issued							$ 287,252	$ 535,787
Shares issued, price per share							$ 0.18
Accrued liabilities for commissions, expense and taxes							$ 142,500
Debt instrument periodic payment				$ 3,000
Equity compensation charges										$ 31,750
Accrued expenses							$ 19,150		$ 19,150
Share based compensation, shares not yet issued									1,500,000
Loss contingency, allegations							The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief.
Consulting Services Agreement [Member] | Restricted Stock [Member]
Defined Benefit Plan Disclosure [Line Items]
Consulting service term			5 years
Common stock shares issued			500,000
Debt instrument, interest rate			8%
Note issued			$ 50,000
Consultant Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Share-based compensation arrangement by share-based payment						2,500,000
Consultant Agreement [Member] | Common Stock [Member]
Defined Benefit Plan Disclosure [Line Items]
Debt instrument periodic payment						$ 3,000
Recepto Pharm Leases [Member]
Defined Benefit Plan Disclosure [Line Items]
Lease, description		ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year.			In February of 2021, we signed an updated lease with extended terms through January 1, 2023. The lease calls for monthly payments of approximately $6,500 with a 4% increase each year.
Lease monthly payments		$ 6,900			$ 6,500
Get Credit Healthy, Inc. and Rik Deitsch [Member]
Defined Benefit Plan Disclosure [Line Items]
Loss contingency, damages sought, value	$ 100,000
CSA 8411, LLC [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term debt							$ 91,156
Accrued interest							$ 60,037

SCHEDULE OF RELATED PARTY BALAN

SCHEDULE OF RELATED PARTY BALANCES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Deferred revenue to a related party	$ 111,011
Accrued interest to a related party	$ 145,508	$ 147,768

SCHEDULE OF RELATED PARTY TRANS

SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Related Party Transactions [Abstract]
Net sales to a related party	$ 84,580		$ 154,966
Bad debt expense (recovery) - related party	(21,799)	(35,000)		38,000
Rental income from a related party	10,000		10,000
Interest expense to a related party	$ 4,272	$ 4,504	$ 12,740	$ 13,881

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	May 31, 2022	Sep. 30, 2022	Sep. 30, 2022
Related Party Transactions [Abstract]
Payment for rent	$ 5,000	$ 10,000	$ 10,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 31, 2022	Oct. 27, 2022	Aug. 31, 2022	Feb. 28, 2022	Jan. 31, 2022
Subsequent Event [Line Items]
Debt instrument unamortized discount			$ 16,693
Promissory Note [Member]
Subsequent Event [Line Items]
Debt instrument unamortized discount			$ 16,693	$ 16,693
Non-related Party [Member] | Promissory Note [Member]
Subsequent Event [Line Items]
Due from related party					$ 199,000
Debt instrument, interest rate, stated percentage					63.76%
Subsequent Event [Member] | Non-related Party [Member] | Promissory Note [Member]
Subsequent Event [Line Items]
Due from related party		$ 199,000
Debt instrument, interest rate, stated percentage		60.73%
Subsequent Event [Member] | Convertible Promissory Notes [Member] | Unrelated Third Parties [Member]
Subsequent Event [Line Items]
Debt instrument, face amount	$ 57,500
Debt instrument unamortized discount	$ 7,500
Debt Instrument, Convertible, Conversion Price	$ 0.0006